SGIP1 is involved in regulation of emotionality, mood, and nociception and modulates in vivo signalling of cannabinoid CB1 receptors

0543888 - ÚMG 2022 RIV GB eng J - Článek v odborném periodiku
Dvořáková, Michaela - Kubik-Zahorodna, Agnieszka - Straiker, A. - Sedláček, Radislav - Hájková, Alena - Mackie, K. - Blahoš, Jaroslav
SGIP1 is involved in regulation of emotionality, mood, and nociception and modulates in vivo signalling of cannabinoid CB1 receptors.
British Journal of Pharmacology. Roč. 178, č. 7 (2021), s. 1588-1604. ISSN 0007-1188. E-ISSN 1476-5381
Grant CEP: GA MŠMT ED2.1.00/19.0395; GA ČR GA19-24172S; GA MŠMT(CZ) LM2015040
Institucionální podpora: RVO:68378050
Klíčová slova: anxiety * cannabinoid receptor 1 * endocannabinoid system * gpcr * pain * tolerance
Obor OECD: Biochemistry and molecular biology
Impakt faktor: 9.473, rok: 2021
Způsob publikování: Omezený přístup
https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15383

Background and Purpose Src homology 3-domain growth factor receptor-bound 2-like endophilin interacting protein 1 (SGIP1) interacts with cannabinoid CB1 receptors. SGIP1 is abundantly and principally expressed within the nervous system. SGIP1 and CB1 receptors co-localize in axons and presynaptic boutons. SGIP1 interferes with the internalization of activated CB1 receptors in transfected heterologous cells. Consequently, the transient association of CB1 receptors with beta-arrestin2 is enhanced and prolonged, and CB1 receptor-mediated ERK1/2 signalling is decreased. Because of these actions, SGIP1 may modulate affect, anxiety, pain processing, and other physiological processes controlled by the endocannabinoid system (ECS).
Trvalý link: http://hdl.handle.net/11104/0321021